Arecor Therapeutics PLC (AIM:AREC) said its subsidiary Tetris Pharma has launched Ogluo, its glucagon-prefilled autoinjector pen, in the Netherlands.
Designed to treat severe hypoglycaemia in individuals with diabetes mellitus, it will be rolled out commercially by Tetris' local partner, Goodlife.
Ogluo was developed to provide a solution for the emergency treatment of severe hypoglycaemic episodes, which can be life-threatening for people with diabetes.
Tetris senior vice president Helen Parris said: "The launch of Ogluo in the Netherlands presents a significant milestone for Tetris Pharma, strengthening the commercial reach and pan-European presence of this important product and giving patients living with diabetes who may experience severe hypoglycaemia, a treatment option to tackle those events.
"Goodlife's leading know-how and expertise of regional market dynamics make them an ideal partner to support with the roll-out of Ogluo in the Benelux region. We look forward to continuing to expand our reach within Europe to bring this treatment option to people living with diabetes."